title: The safety of treatment options for elderly people with acute myeloid leukemia.
abstract: BACKGROUND
  Life expectancy in elderly patients with acute myeloid leukemia (AML) is a function of age, disability, and co-morbidity, combined with leukemia characteristics. There is currently no consensus regarding the optimal therapeutic strategy for older adults with AML. Although selected older adults with AML can benefit from intensive therapies, recent evidence supports the use of lower-intensity therapies in most patients and emphasizes the importance of tolerability and quality of life.
  
  
  METHODS
  Results of the current clinical trials and safety data are reviewed.
  
  
  CONCLUSIONS
  Treatment recommendations for elderly patients with AML need to be individualized. In order to avoid toxicities, hematologists should collaborate more with geriatricians to identify clues of vulnerability in elderly patients through the study of functional physical, physiological, cognitive, social, and psychological parameters.
authors.affiliation: a Hematology Department , Hospices Civils de Lyon, Lyon-Sud Hospital , Pierre-Bénite , France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Thomas
authors.affiliation: a Hematology Department , Hospices Civils de Lyon, Lyon-Sud Hospital , Pierre-Bénite , France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Le Jeune
mesh_terms: D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003299:Cooperative Behavior; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents
keywords: Acute myeloid leukemia; chemotherapy; elderly; hypomethylating agents; safety profile; targeted therapy